(Q34229618)

31 July 2017

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (English)

1 reference

multicenter clinical trial

31 July 2017

phase II clinical trial

0 references

placebo

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

0 references

1

Ludwig Kappos

1 reference

31 July 2017

6

Frederik Barkhof

1 reference

31 July 2017

3

Peter A Calabresi

1 reference

31 July 2017

5

Amit Bar-Or

1 reference

31 July 2017

11

Stephen L Hauser

1 reference

31 July 2017

David Li

2

1 reference

31 July 2017

Paul O'Connor

4

1 reference

31 July 2017

Ming Yin

7

1 reference

31 July 2017

David Leppert

8

1 reference

31 July 2017

Robert Glanzman

9

1 reference

31 July 2017

Jeroen Tinbergen

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

31 October 2011

1 reference

31 July 2017

1 reference

31 July 2017

378

1 reference

31 July 2017

9805

1 reference

31 July 2017

1779-1787

1 reference

Autoimmune inflammation from the Th17 perspective

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

B-cell differentiation in the CNS of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961649-8

7 January 2021

10.1016/S0140-6736(11)61649-8

Identifiers

DOI

1 reference

31 July 2017

1 reference